Singular Genomics Systems (NASDAQ:OMIC) Announces Earnings Results, Beats Estimates By $1.33 EPS

Singular Genomics Systems (NASDAQ:OMIC) issued its quarterly earnings results on Tuesday. The company reported ($6.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.05) by $1.33, Zacks reports. The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.74 million. Singular Genomics Systems had a negative return on equity of 54.70% and a negative net margin of 3,237.89%.

Singular Genomics Systems Price Performance

Singular Genomics Systems stock opened at $22.53 on Thursday. The stock has a market capitalization of $56.33 million, a P/E ratio of -0.64 and a beta of 1.51. The company’s fifty day moving average price is $14.99 and its 200 day moving average price is $11.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.04 and a current ratio of 8.77. Singular Genomics Systems has a 1 year low of $5.34 and a 1 year high of $23.41.

Singular Genomics Systems Company Profile

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.